Pharma BD Deal Intelligence

Roche Holding AG / Genia Technologies, Inc.

2014 · Acquisition/Merger · $350M · Complete

Announcement Sentiment

Strongly positive

Roche acquired Mountain View-based Genia Technologies for $125M upfront plus up to $225M in milestones, gaining a single-molecule nanopore sequencing platform after Roche's earlier failed PacBio deal. The deal positioned Roche to compete in clinical NGS against Illumina and Thermo.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Stalled

Assessment window: 5yr post-close.

Key facts

Announced Jun 02, 2014
Closed Jun 02, 2014
Deal value $350M
Deal type Acquisition/Merger
Therapeutic area Next-generation sequencing diagnostics
Indications Next-generation sequencing diagnostics
Key assets Single-molecule nanopore DNA sequencing platform
Mechanism Nanopore-based electrical detection of nucleic acid bases

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals